Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 719

1.

Reduced Angiopoietin-Like 4 Expression in Multiple Sclerosis Lesions Facilitates Lipid Uptake by Phagocytes via Modulation of Lipoprotein-Lipase Activity.

Kamermans A, Rijnsburger M, Chakraborty A, van der Pol S, de Vries HE, van Horssen J.

Front Immunol. 2019 May 3;10:950. doi: 10.3389/fimmu.2019.00950. eCollection 2019.

2.

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.

Pol S, Fontaine H, Carrat F; on the behalf of the ANRS/AFEF Hepather Study group.

J Hepatol. 2019 May 23. pii: S0168-8278(19)30186-2. doi: 10.1016/j.jhep.2019.02.025. [Epub ahead of print] No abstract available.

PMID:
31130438
3.

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 May 21. doi: 10.1007/s11136-019-02204-x. [Epub ahead of print]

PMID:
31115842
4.

Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.

Cossais S, Schwarzinger M, Pol S, Fontaine H, Larrey D, Pageaux GP, Canva V, Mathurin P, Yazdanpanah Y, Deuffic-Burban S.

PLoS One. 2019 May 3;14(5):e0215596. doi: 10.1371/journal.pone.0215596. eCollection 2019.

5.

The remarkable history of the hepatitis C virus.

Pol S, Lagaye S.

Genes Immun. 2019 May;20(5):436-446. doi: 10.1038/s41435-019-0066-z. Epub 2019 Apr 25.

PMID:
31019253
6.

Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.

Younossi ZM, Stepanova M, Jacobson I, Muir AJ, Pol S, Zeuzem S, Younes Z, Herring R, Lawitz E, Younossi I, Racila A.

Clin Infect Dis. 2019 Apr 5. pii: ciz243. doi: 10.1093/cid/ciz243. [Epub ahead of print]

PMID:
30949674
7.

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group.

BMC Infect Dis. 2019 Apr 2;19(1):300. doi: 10.1186/s12879-019-3923-5.

8.

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II).

Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N.

Health Sci Rep. 2019 Mar 1;2(3):e92. doi: 10.1002/hsr2.92. eCollection 2019 Mar.

9.

Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 Mar 23. doi: 10.1007/s11136-019-02148-2. [Epub ahead of print] Erratum in: Qual Life Res. 2019 May 21;:.

PMID:
30905021
10.

Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients.

D'Ambrosio R, Vinci M, Franchina M, Parlati L, Zaltron S, Pasulo L, Campise M, Messa P, Pol S, Lampertico P.

Kidney Int. 2019 Apr;95(4):993-995. doi: 10.1016/j.kint.2018.11.037. No abstract available.

PMID:
30904073
11.

Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.

Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P.

J Hepatol. 2019 May;70(5):831-838. doi: 10.1016/j.jhep.2018.12.036. Epub 2019 Mar 14.

PMID:
30879789
12.

[Hepatitis virus infection: key messages].

Pol S.

Rev Prat. 2018 Mar;68(3):293. French. No abstract available.

PMID:
30869289
13.

[Hepatitis C facing the challenge of healing].

Pol S.

Rev Prat. 2018 Mar;68(3):269-275. French.

PMID:
30869284
14.

[Viral hepatitis: vaccinate and screen?]

Pol S.

Rev Prat. 2018 Mar;68(3):267-268. French. No abstract available.

PMID:
30869283
15.

Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?

Pol S, Vallet-Pichard A, Fontaine H, Carrat F.

Liver Int. 2019 Mar;39(3):446-447. doi: 10.1111/liv.14029. No abstract available.

PMID:
30793527
16.

Direct acting antivirals failure: cause and retreatment options.

Parlati L, Pol S.

Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1245-1250. doi: 10.1080/17474124.2018.1541237. Epub 2018 Oct 31.

PMID:
30791789
17.

[Elimination of hepatitis C virus infection].

Pol S.

Presse Med. 2019 Jan;48(1 Pt 1):1-3. doi: 10.1016/j.lpm.2019.01.001. French. No abstract available.

PMID:
30784420
18.

Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth.

Hollande C, Boussier J, Ziai J, Nozawa T, Bondet V, Phung W, Lu B, Duffy D, Paradis V, Mallet V, Eberl G, Sandoval W, Schartner JM, Pol S, Barreira da Silva R, Albert ML.

Nat Immunol. 2019 Mar;20(3):257-264. doi: 10.1038/s41590-019-0321-5. Epub 2019 Feb 18.

PMID:
30778250
19.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.

PMID:
30768988
20.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.

Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.

PMID:
30767274

Supplemental Content

Loading ...
Support Center